Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | DNM1 | Q05193 | 8/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.33 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23806431 | 0.96 | OPRM1 (0.39) | OPRM1DNM1MEN1KMT2AALDH1A1 | |
| SCHEMBL31230828 | 0.78 | TSHR (0.36) | OPRM1DNM1TSHRLMNA | |
| SCHEMBL8941195 | 0.75 | LMNA (0.37) | OPRM1DNM1TSHRSPHK1LMNA | |
| SCHEMBL24972730 | 0.75 | OPRM1 (0.44) | OPRM1DNM1MEN1KMT2AALDH1A1 | |
| SCHEMBL19432981 | 0.74 | DNM1 (0.39) | OPRM1DNM1MEN1KMT2AALDH1A1 | |
| SCHEMBL19434123 | 0.74 | CYP3A4 (0.37) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL20331217 | 0.74 | OPRM1 (0.37) | OPRM1DNM1TSHRSPHK1LMNA | |
| SCHEMBL7122689 | 0.72 | DNM1 (0.42) | DNM1TSHR | |
| SCHEMBL9374804 | 0.72 | SPHK1 (0.41) | OPRM1DNM1TSHRSPHK1LMNA | |
| SCHEMBL14989365 | 0.72 | SPHK1 (0.41) | OPRM1DNM1TSHRSPHK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | OPRM1 3231/4885DNM1 2603/4885MEN1 2745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.